Forbes reports that methamphetamine use is on the rise in the US. However, the rise is “overshadowed by the rise in opioid abuse and fatal overdoses.” The National Institute of Drug Abuse (NIDA) is making research on a treatment for methamphetamine addiction a priority. One drug currently in development, Ibudilast, “has shown promise in reducing inflammation in the brains of rats, and reduces self-administration of methamphetamine.” In 2016, Ibudilast received Fast Track designation from the FDA “to help speed development as a potential treatment for multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).” The drug is still in trials.

From the news release of the American Association for Justice.